Objective: Patients with metastatic colorectal cancer are now recommended to profile for RAS and BRAF mutations before receiving cetuximab or panitumumab.Ho
Objective: The prognosis for unresectable metastatic colorectal cancers is poor, and improved therapies are needed.Recent studies have shown the activated N
Objective: Cytokine-induced killer (CIK) cells represent a realistic approach in cancer immunotherapy with confirmed survival benefits in the context of met
Objective: To evaluate radiochemotherapeutic sequence for pathological stage N2 rectal cancer in the era of oxaliplatin-based adjuvant therapy.Method: Treat